ERBB2 and breast cancer: HER2 amplification and overexpression have been reported in 18–25% of breast cancer, as well as in subsets of patients with gastric carcinoma, esophageal cancer, salivary gland tumor, and ovarian cancers [17, 18, 28, 69–71].